Loss of the xeroderma pigmentosum group B protein binding site impairs p210 BCR/ABL1 leukemogenic activity

Blood Cancer Journal

Volumn 3, Issue 8, 2013, Pages

  Pannucci, N L ^a   Li, D ^a   Sahay, S ^a   Thomas, E K ^b   Chen, R ^a   Tala, I ^a   Hu, T ^a   Ciccarelli, B T ^a   Megjugorac, N J ^a   Adams III, H C ^a   Rodriguez, P L ^a   Fitzpatrick, E R ^a   Lagunoff, D ^a   Williams, D A ^c   Whitehead, I P ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Chronic myelogenous leukemia; DNA repair; NER; p210 BCR ABL1; XPB

Indexed keywords

BCR ABL PROTEIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MUTANT PROTEIN; NUCLEIC ACID BINDING PROTEIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP B PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLONOGENESIS; COMET ASSAY; CONTROLLED STUDY; DISEASE COURSE; EXCISION REPAIR; FEMALE; GENE EXPRESSION; IMMUNOPHENOTYPING; IMMUNOPRECIPITATION; LEUKEMOGENESIS; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL; MOUSE; MYELOID PROGENITOR CELL; MYELOPROLIFERATIVE DISORDER; NONHUMAN; NUCLEOTIDE BINDING SITE; ONCOGENE C MYC; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 84882991660     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.36     Document Type: Article

References (42)

1. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375-2384 (Pubitemid 26327486)
2. Muller AJ, Young JC, Pendergast AM, Pondel M, Landau NR, Littman DR et al. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol 1991; 11: 1785-1792 (Pubitemid 21895544)
3. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 1993; 13: 7587-7595 (Pubitemid 23354283)
4. Maru Y, Afar DE, Witte ON, Shibuya M. The dimerization property of glutathione S-transferase partially reactivates Bcr-Abl lacking the oligomerization domain. J Biol Chem 1996; 271: 15353-15357 (Pubitemid 26225302)
5. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N et al. BCR-ABLinduced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75: 175-185 (Pubitemid 23306031)
6. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103: 4010-4022 (Pubitemid 38685338)
7. Dierov J, Dierova R, Carroll M. BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer cell 2004; 5: 275-285 (Pubitemid 38402119)
8. Skorski T. BCR/ABL, DNA damage and DNA repair: Implications for new treatment concepts. Leuk Lymphoma 2008; 49: 610-614 (Pubitemid 351517197)
9. Bedi A, Barber JP, Bedi GC, el-Deiry WS, Sidransky D, Vala MS et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 1995; 86: 1148-1158
10. Fuchs EJ, Bedi A, Jones RJ, Hess AD. Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. Cancer Res 1995; 55: 463-466
11. Papazisis KT, Zambouli D, Kimoundri OT, Papadakis ES, Vala V, Geromichalos GD et al. Protein tyrosine kinase inhibitor, genistein, enhances apoptosis and cell cycle arrest in K562 cells treated with gamma-irradiation. Cancer Lett 2000; 160: 107-113
12. Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001; 8: 795-806 (Pubitemid 33030213)
13. van der Kuip H, Goetz AW, Miething C, Duyster J, Aulitzky WE. Adhesion to fibronectin selectively protects Bcr-Abl cells from DNA damage-induced apoptosis. Blood 2001; 98: 1532-1541
14. Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 2002; 22: 4189-4201 (Pubitemid 34556589)
15. Canitrot Y, Falinski R, Louat T, Laurent G, Cazaux C, Hoffmann JS et al. p210 BCR/ ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood 2003; 102: 2632-2637 (Pubitemid 37193605)
16. Laurent E, Mitchell DL, Estrov Z, Lowery M, Tucker SL, Talpaz M et al. Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair. Clin Cancer Res 2003; 9(10 Pt 1): 3722-3730 (Pubitemid 37169241)
17. Shuck SC, Short EA, Turchi JJ. Eukaryotic nucleotide excision repair: From understanding mechanisms to influencing biology. Cell Res 2008; 18: 64-72
18. Maru Y, Kobayashi T, Tanaka K, Shibuya M. BCR binds to the xeroderma pigmentosum group B protein. Biochem Biophys Res Commun 1999; 260: 309-312 (Pubitemid 29352062)
19. Takeda N, Shibuya M, Maru Y. The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein. Proc Natl Acad Sci USA 1999; 96: 203-207 (Pubitemid 29036077)
20. Roy R, Schaeffer L, Humbert S, Vermeulen W, Weeda G, Egly JM. The DNA-dependent ATPase activity associated with the class II basic transcription factor BTF2/TFIIH. J Biol Chem 1994; 269: 9826-9832 (Pubitemid 24196591)
21. Schaeffer L, Roy R, Humbert S, Moncollin V, Vermeulen W, Hoeijmakers JH et al. DNA repair helicase: A component of BTF2 (TFIIH) basic transcription factor. Science 1993; 260: 58-63 (Pubitemid 23122745)
22. van Vuuren AJ, Vermeulen W, Ma L, Weeda G, Appeldoorn E, Jaspers NG et al. Correction of xeroderma pigmentosum repair defect by basal transcription factor BTF2 (TFIIH). EMBO J 1994; 13: 1645-1653 (Pubitemid 24114716)
23. Sahay S, Pannucci NL, Mahon GM, Rodriguez PL, Megjugorac NJ, Kostenko EV et al. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation. Oncogene 2008; 27: 2064-2071 (Pubitemid 351442739)
24. Mahon GM, Wang Y, Korus M, Kostenko E, Cheng L, Sun T et al. The c-Myc Oncoprotein Interacts with Bcr. Curr Biol 2003; 13: 437-441 (Pubitemid 36280464)
25. Van Parijs L, Refaeli Y, Lord JD, Nelson BH, Abbas AK, Baltimore D. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity 1999; 11: 281-288 (Pubitemid 29463236)
26. Naviaux RK, Costanzi E, Haas M, Verma IM. The pCL vector system: Rapid production of helper-free, high-titer, recombinant retroviruses. J Virol 1996; 70: 5701-5705 (Pubitemid 26240755)
27. Tala I, Chen R, Hu T, Fitzpatrick ER, Williams DA, Whitehead IP. Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression. Leukemia 27: 1080-1089
28. Olabisi OO, Mahon GM, Kostenko EV, Liu Z, Ozer HL, Whitehead IP. Bcr interacts with components of the endosomal sorting complex required for transport-I and is required for epidermal growth factor receptor turnover. Cancer Res 2006; 66: 6250-6257
29. ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia leukemia. Blood 1994; 84: 1731-1736 (Pubitemid 24286120)
30. Sawyers CL. The role of myc in transformation by BCR-ABL. Leuk Lymphoma 1993; 11(Suppl 1): 45-46 (Pubitemid 23274135)
31. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992; 70: 901-910
32. Liu J, Kouzine F, Nie Z, Chung HJ, Elisha-Feil Z, Weber A et al. The FUSE/FBP/FIR/ TFIIH system is a molecular machine programming a pulse of c-myc expression. EMBO J 2006; 25: 2119-2130
33. Weber A, Liu J, Collins I, Levens D. TFIIH operates through an expanded proximal promoter to fine-tune c-myc expression. Mol Cell Biol 2005; 25: 147-161 (Pubitemid 40039807)
34. Li S, Ilaria Jr RL, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189: 1399-1412 (Pubitemid 29227526)
35. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92: 3780-3792 (Pubitemid 28525205)
36. Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colonystimulating factor in mice: A novel model for chronic myelogenous leukemia. Blood 1998; 92: 3829-3840 (Pubitemid 28525209)
37. Stewart MJ, Litz-Jackson S, Burgess GS, Williamson EA, Leibowitz DS, Boswell HS. Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells. Leukemia 1995; 9: 1499-1507
38. Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 2000; 96: 2269-2276
39. Gustafson WC, Ray S, Jamieson L, Thompson EA, Brasier AR, Fields AP. Bcr-Abl regulates protein kinase Ciota (PKCiota) transcription via an Elk1 site in the PKCiota promoter. J Biol Chem 2004; 279: 9400-9408 (Pubitemid 38296006)
40. Ghaffari S, Jagani Z, Kitidis C, Lodish HF, Khosravi-Far R. Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci USA 2003; 100: 6523-6528 (Pubitemid 36666614)
41. Hickey FB, Cotter TG. Identification of transcriptional targets associated with the expression of p210 Bcr-Abl. Eur J Haematol 2006; 76: 369-383
42. Liu J, He L, Collins I, Ge H, Libutti D, Li J et al. The FBP interacting repressor targets TFIIH to inhibit activated transcription. Mol Cell 2000; 5: 331-341 (Pubitemid 30628091)